Lenalidomid v léčbě mnohočetného myelomu
| Title in English | Lenalidomide (Revlimid) in the treatment of multiple myeloma |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | lenalidomid; revlimid; multiple myeloma |
| Description | Over the past 5 years, lenalidomide (Revlimid, Celgene Co., Summit, NJ, USA), a member of a class of drugs termed immunomodulatory drugs, has emerged as a significant weapon in the arsenal of cancer-therapeutics. The following review describes key clinical and mechanistic breakthroughs that have made lenalidomide a leading cancer therapeutic. |